Global Human Recombinant Insulin Market Benchmarking of the Top Players (Biocon, Bioton S.A., Eli Lilly and Company) Forecast 2023

Human Recombinant Insulin Market Report Coverage Highlights: This report covers drivers, restraints, opportunities, challenges, and market trends. The report also covers the product portfolio analysis of the Human Recombinant Insulin products and vendor benchmarking of the top players in this market. In addition, this report highlights the growth strategies adopted by the major market players to garner large shares in the Human Recombinant Insulin market.

A separate section with Human Recombinant Insulin industry key players is included in the report, which provides a comprehensive analysis of price, cost, gross, revenue, product picture, specifications, company profile, and contact information. Development and Research plays a vital role towards the innovation in any given industry which require to execute. Additionally, performing research and development offers a competitive advantage over the competitors owing to regular introduction of products and prototypes to attract consumers. This is expected to have a positive impact on the Human Recombinant Insulin market growth over the forecast period.

Request a Sample of this report from:

https://www.marketreportsworld.com/enquiry/request-sample/12347504

The global human recombinant insulin market is projected to grow at a CAGR of approximately 7.2% during the forecast period (2018 - 2023). Recombinant human insulin is the synthetic insulin which was developed using recombinant DNA technology by harvesting insulin proteins within Escherichia coli (E.coli).

Increasing Prevalence of Diabetes around the World Boost the Growth of Human Recombinant Insulin Market

Diabetes is one of the most malignant diseases of the 21st century. According to WHO, it has been predicted that diabetes would be the seventh most-leading cause of death by 2030. According to Diabetes UK, in 2017, there are almost 3.7 million people diagnosed with diabetes in the UK and it has been estimated that up to 549,000 people in the country have diabetes that is yet to be diagnosed. Obesity is the most potent factor for Type 2 diabetes, which accounts for 80-85% of overall risk of developing Type 2 diabetes. As per Diabetes UK 2016, almost two in every three people in the UK are overweight or obese, in which 59% are women and 68% are men. So, due to the exponential rise in the prevalence of diabetes there is an urgent demand for establishing effective diabetes therapy in countries which are burdened by inadequate health care budgets, malnutrition and infectious diseases. Also, Recombinant human insulin has replaced animal insulin and animal-based semisynthetic human insulin thereby available in sufficient quantities and at affordable prices able to provide global access to insulin therapy. Additionally, technological advancement in drug delivery devices and increasing investments in diabetes research activities are also spurring the growth of the market.

High Cost of Recombinant Insulin Hindering Human Recombinant Insulin Market

High cost of the recombinant insulin is restraining the growth of the market as many patients from low and middle income countries are unable to afford these recombinant insulin. According to the Pharmaceutical Care Management Association (PCMA), May 2018 report, prices of recombinant insulin have increased over 10-fold since 1985 and prices have exhibited significant rise during the last past 10 years (2008 to 2018). According to PCMA, cost of Humulin/Novolin have also increased. Thus high cost of recombinant insulin is acting as a major barrier for the growth of the market. Also, risks associated with recombinant insulin is also hindering the growth of the human recombinant insulin market.

North America has the Largest Share in Global Human Recombinant Insulin Market

The largest share of North America is attributed due to the fact that there is an increasing prevalence of diabetes in the US as according to The American Diabetes Association (ADA) it has been estimated that the total cost of known diabetes in the US rose by about 40% over a five-year period from 2011-2016 which represents 20% of all healthcare dollars in the USA.

Key Developments in the Human Recombinant Insulin Technology Market

Jun 2018: Eli Lilly and Company’s Humulin R U-500 which was administered in an insulin pumps showed greater A1C reduction in adults with type 2 diabetes which was compared to multiple daily injections (MDI).
Jul 2018: Eli Lilly and Company established a helpline called as Lilly Diabetes Solution Center for assisting people that need help paying for their insulin.

Market Major players: BIOCON, BIOTON S.A., ELI LILLY AND COMPANY, GAN & LEE PHARMACEUTICALS, LTD., JULPHAR GULF PHARMACEUTICAL INDUSTRIES, NOVO NORDISK A/S, SANOFI S.A., and ZHUHAI UNITED LABORATORIES CO., LTD among others.

Reasons to Purchase Human Recombinant Insulin Market Report

Current and future global human recombinant insulin market outlook in the developed and emerging markets
Analyzing various perspectives of the market with the help of Porters five forces analysis
The segment that is expected to dominate the market
Regions that are expected to witness fastest growth during the forecast period
Identify the latest developments, market shares and strategies employed by the major market players.
3-month analyst support along with the market estimate sheet (in Excel).

Customization of Human Recombinant Insulin Market Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

Browse Full Report at: -

https://www.marketreportsworld.com/12347504

Human Recombinant Insulin Market Forecast 2018-2023

The Human Recombinant Insulin industry research report analyses the supply, sales, production, and market status comprehensively. Production market shares and sales market shares are analysed along with the study of capacity, production, sales, and revenue. Several other factors such as import, export, gross margin, price, cost, and consumption are also analysed under the section Analysis of Human Recombinant Insulin production, supply, sales and market status.

Lastly, this report covers the market landscape and its growth prospects over the coming years, the Report also brief deals with the product life cycle, comparing it to the relevant products from across industries that had already been commercialized details the potential for various applications, discussing about recent product innovations and gives an overview on potential regional market shares.

Detailed TOC of Global Human Recombinant Insulin Market Forecasts (2018 - 2023)

Introduction
1.1 Definition of the Market

1.2 Key Findings of the Study

Research Scope and Methodology
2.1 Study Deliverables

2.2 Study Assumptions

2.3 Research Methodology

2.4 Research Phases

Market Dynamics
3.1 Drivers

3.1.1 Increasing Demand for Human Recombinant Insulin

3.1.2 Evolving R&D Priorities

3.1.3 Adoption of Human Recombinant Insulin

3.2 Restraints

3.2.1 Human Recombinant Insulin Industry

3.2.2 Human Recombinant Insulin Types and Application

Industry Analysis
4.1 Porter's Five Forces Analysis

4.1.1 Bargaining Power of Suppliers

4.1.2 Bargaining Power of Buyers

4.1.3 Threats of New Entrants

4.1.4 Threats of Substitute Products and Services

4.1.5 Degree of Competition

Market Segmentation
5.1 By Application

5.2 By Geography

5.2.1 North America

5.2.1.1 US

5.2.1.2 Canada

5.2.1.3 Mexico

5.2.1.4 Others

5.2.2 Europe

5.2.2.1 Spain

5.2.2.2 UK

5.2.2.3 France

5.2.2.4 Germany

5.2.2.5 Russia

5.2.2.6 Italy

5.2.2.7 Others

5.2.3 Asia-Pacific

5.2.3.1 China

5.2.3.2 Japan

5.2.3.3 India

5.2.3.4 Australia

5.2.3.5 Others

5.2.4 South America

5.2.4.1 Brazil

5.2.4.2 Argentina

5.2.4.3 Others

5.2.5 Africa

5.2.5.1 South Africa

5.2.5.2 Others

Competitor Analysis
6.1 Market Shares of Leading Players

6.2 Strategies Adopted by Leading Players

Company Profiles
Future Outlook of the Market
Appendix
Price of Report (single User Licence): $4250

Purchase the Human Recombinant Insulin Market Report at:

https://www.marketreportsworld.com/purchase/12347504

Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided today’s businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors. Market Reports World is the credible source for gaining the market reports that will provide you with the lead your business needs.

Market Reports World

3rd Floor, Silver Spring, Sahyadri farms,

Opp Prabhavee Tech Park,

Baner - Mhalunge Road, Baner, Pune 411045.

This release was published on openPR.